J&J may not be far behind.
Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded
AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now, European Medical Agency (EMA) is investigating potential clotting risks from Johnson & Johnson’s (NYSE: JNJ) one-shot COVID-19 vaccine.
What Happened: While AstraZeneca has been caught in a frenzy over possible links to rare blood clots and subsequent restriction on the usage of its vaccine, this is a formal disclosure of the J&J probe.
So far, four severe cases of rare blood clots with low platelets have been reported after inoculation with J&J’s vaccine.
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) said three cases of unusual blood clots with low blood platelets followed the vaccination. Another issue came in a clinical trial.
Why It Matters: All four were “serious cases,” the committee says. The reports “point to a ‘safety signal,’ but it is currently not clear whether there is a causal association,” PRAC says.
So far, the JNJ vaccine is only available in the U.S., but European officials recently authorized the jab, and the rollout is expected to start soon.
Meanwhile, the U.S. rollout of the JNJ vaccine has run into some problems. Just 785,000 doses are set to ship out to states next week, down from 4.9 million this week.
Excerpt.
I have a family history of atheroscerosis aka hardening of the veins aka narrowing/clogging of the veins. No clotting vaccines for me.